OX338 - Moderate to moderately severe pain

Short facts  
API Ketorolac
Technology Sublingual
Indication Moderate to moderately severe pain
Development phase Finalized phase 1
Expected filing with FDA -
In-house or partnership In-house

Unmet need
Opioids are still used unnecessarily in many situations, further fueling the opioid crisis.

Our aim
Based on Orexo´s novel oral formulation technology, the aim is to develop an opioid-level pain relief treatment for short-term pain (up to 5 days) without the risk of addiction.

Results from the exploratory PK-study in healthy volunteers showed significant better PK-profile, such as faster uptake and higher peak, when compared to nasal spray available on the market.